Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells.

Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second

Is your dog undergoing surgery for a ruptured splenic tumor? Ethos Discovery would love to have you and your dog participate in our clinical trial! We are evaluating drugs for the treatment of HSA with the goal of curing this aggressive cancer.

This study aims to determine whether or not canine patients diagnosed with canine osteosarcoma (OSA) have intestinal dysbiosis and whether treating intestinal disease improves patient outcomes.

We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

This study seeks to understand the intestinal absorption potential of a novel formulation of rapamycin when administered to dogs with naturally occurring cancer. The data from this study will be used to define an ideal dose of the drug to use in future cancer clinical studies.